Needham starts Galena Biopharma (GALE +4.1%) at Buy with $3.50 price target. When administered...


Needham starts Galena Biopharma (GALE +4.1%) at Buy with $3.50 price target. When administered as an adjuvant, the investment bank says the company's breast cancer vaccine NeuVax shows promise. The vaccine is "one of the leading new product candidates" for adjuvant vaccine therapy which analyst Chad Messer says will "become the standard of care for many cancer types." The company recently acquired Abstral, a sublingual tablet indicated for cancer pain which notched $54M in sales in Europe last year, for sale and distribution in the U.S. 

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs